Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings?

ADMA Biologics (ADMA) is scheduled to report third-quarter 2024 results on Nov. 7, after market close.The Zacks Consensus Estimate for sales and earnings is pegged at $107.25 million and 13 cents per share, respectively.Image Source: Zacks Investment ResearchFind the latest EPS estimates and surprises on Zacks Earnings Calendar.ADMA’s Earnings Surprise HistoryADMA has an excellent track record. ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 105.63%. I ...